Under the terms of the collaboration agreement, Merck funds costs of development and commercialization of products that employ MicroDose’s DPI technology for the administration of Merck compounds.  MicroDose is eligible to receive milestone payments and royalties on revenues from all products developed under the agreement.

“We are excited to announce the expansion of our collaboration with Merck to include an additional compound for development in our inhaler,” said Michael J. Martin, Vice President, Licensing & Business Development, at MicroDose.  “This step provides a further indication of Merck’s commitment to pulmonary delivery and to the MicroDose inhaler, and once again demonstrates the ability of the technical teams at both MicroDose and Merck to quickly and efficiently evaluate the feasibility and initiate the development of promising new therapies.”

About MicroDose Therapeutx
MicroDose Therapeutx is dedicated to improving the quality of life for people suffering from serious diseases by creating improved pharmaceutical products.  The company is a leader in the application of proprietary drug delivery technologies, developing advanced pulmonary, combination oral dosage, and other technologies and products for the pharmaceutical and biotechnology industries.

About the MicroDose Dry Powder Inhaler (DPI)
The MicroDose DPI is among a number of key proprietary drug delivery technologies developed by MicroDose.  By employing piezo electronics, the MicroDose DPI has the potential to deliver enhanced performance as compared to other inhalers, offering efficient and reproducible delivery independent of patient coordination, inhalation rate and posture.  MicroDose believes that the flexibility of the inhaler makes it a true platform technology, able to support a broad pipeline of products across the spectrum of patient populations and therapeutic categories.

Contact: Scott Fleming, Senior V.P., Sales & Marketing at 732-355-2114 or sfleming@mdtx.com
Judith Fleischer, Ex Machina D x M, 908-469-0554 or jfleischer@exmachinadxm.com

As previously announced, Merck will fund development and commercialization of products that employ MicroDose’s DPI technology for the administration of Merck compounds. In addition to the upfront payment received upon commencement of the collaboration, MicroDose is eligible for additional milestone payments on this product and for the development of other products and royalties on revenues from all products developed under the license.

“MicroDose is proud to announce the start of the study by Merck which, in fact, represents the second human clinical study to be initiated under a U.S. Investigational New Drug application using our inhaler technology in the last 18 months” commented David Byron, Vice President of Research and Development, MicroDose. “Achieving this milestone with Merck so quickly is a strong indicator of the excellent working relationship that underpins this collaboration.”

About the MicroDose DPI The MicroDose DPI is among a number of key proprietary drug delivery platforms developed by MicroDose. By employing piezo electronics, the MicroDose DPI has the potential to deliver enhanced performance for efficient and reproducible delivery independent of patient coordination, inhalation rate and posture, features MicroDose hopes will be confirmed through clinical trials. MicroDose believes that the flexibility of the
inhaler makes it a true platform technology, able to support a broad pipeline of products across the spectrum of patient populations and therapeutic categories.

About MicroDose Technologies

MicroDose Technologies, Inc., based in Monmouth Junction, New Jersey, is a leading privately-held drug delivery systems company, developing advanced pulmonary, fixed-dose-combination oral dosage, and other technologies for the pharmaceutical and biotechnology industries. In addition to the collaboration with Merck, MicroDose’s other partnerships include; a multi-product development and licensing agreement with Novartis, the development of an inhaled insulin product through MicroDose’s QDose joint venture, and an inhaler for the systemic delivery of a nerve agent antidote for the U.S. Department of Defense, in collaboration with the University of Pittsburgh.

MicroDose has ongoing feasibility programs with other major pharmaceutical companies and is also conducting internal development programs for products employing its inhaler technology, and for combination oral dosage products employing its PolyCap(TM) technology, in the areas of diabetes, hypertension and hyperlipidemia.

For more information visit us at http://www.microdose-tech.com
SOURCE MicroDose Technologies, Inc

Under the terms of the agreement, Merck will fund development and commercialization of products that employ MicroDose’s DPI technology for the administration of Merck compounds. MicroDose will receive an upfront payment and will be eligible for milestone payments totaling $32 million for successful development of the first product as well as royalties on product revenues. Additional products will also be eligible for milestones and royalties.

“We are delighted to expand our relationship with Merck, who have already proved to be very collaborative and decisive in their actions,” commented Scott Fleming, Senior Vice President, Marketing of MicroDose. “This agreement to bring innovative inhalation products to market is a positive milestone in the continued growth of MicroDose and represents further validation of our DPI technology.”

“Through this agreement Merck has gained access to a novel delivery technology that has the potential to facilitate the
administration of and ensure patient compliance with drug treatments targeting the lungs,” said Soren Bo Christiansen, General Manager Bone, Respiratory, Immunology and Endocrine Franchise, Merck & Co., Inc. “This approach is consistent with our leadership strategy of developing respiratory medicines that address unmet medical needs and deliver value to patients, physicians and payers.”

About MicroDose DPI

The MicroDose DPI is among a number of key proprietary drug delivery platforms developed by MicroDose. By employing piezo electronics, the MicroDose DPI has the potential to deliver enhanced performance, versus other inhalers, for efficient and reproducible delivery independent of patient coordination, inhalation rate and posture. MicroDose believes that the flexibility of the inhaler makes it a true platform technology, able to support a broad pipeline of products across the spectrum of patient populations and therapeutic categories.

About MicroDose Technologies MicroDose Technologies, Inc., based in Monmouth Junction, New Jersey, is a leading privately-held drug delivery systems company, developing advanced pulmonary, fixed-dose-combination oral dosage, and other technologies for the pharmaceutical and biotechnology industries.

MicroDose’s partnered programs include; a multi-product development and licensing agreement with Novartis, the development of an inhaled insulin product through MicroDose’s QDose joint venture, and an inhaler for the systemic delivery of a nerve agent antidote for the US Department of Defense, in collaboration with the University of Pittsburgh. MicroDose is also conducting internal development programs for products employing its inhaler technology and for combination oral dosage products, employing its PolyCap(TM) technology, in the areas of diabetes, hypertension and hyperlipidemia.

For more information visit us at http://www.microdose-tech.com
Website: http://www.microdose-tech.com//

MicroDose’s partnered programs include; a multi-product development and licensing agreement with Novartis, the development of an inhaled insulin product through MicroDose’s QDose joint venture, and an inhaler for the systemic delivery of a nerve agent antidote for the US Department of Defense, in collaboration with the University of Pittsburgh. MicroDose is also conducting internal development programs for products employing its inhaler technology and for combination oral dosage products, employing its PolyCap(TM) technology, in the areas of diabetes, hypertension and hyperlipidemia.

For more information visit us at http://www.microdose-tech.com
Website: http://www.microdose-tech.com//

Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996-2008 PR Newswire Association LLC. All Rights Reserved.
A United Business Media company